Ceftazidime in the treatment of lower respiratory tract infection.
Forty patients with acute lower respiratory tract infection requiring hospital admission were treated with ceftazidime. One patient developed acute dyspnoea after the first dose of the drug which was considered to be drug related and treatment was discontinued. All remaining patients were clinically assessed as being either cured or improved. In all cases that were bacteriologically assessable the pathogens were eradicated. One patient developed erythema multiforme after the end of ceftazidime treatment; this was considered to be possibly drug related.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000707:Anaphylaxis / Q000139:chemically induced; D002442:Ceftazidime; D002511:Cephalosporins / Q000009:adverse effects / Q000627:therapeutic use*; D004892:Erythema Multiforme / Q000139:chemically induced; D005260:Female; D006192:Haemophilus Infections / Q000188:drug therapy*; D006193:Haemophilus influenzae; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013183:Sputum / Q000382:microbiology; D013997:Time Factors
D002511:Cephalosporins; D002442:Ceftazidime